GlassScriptPhysician profile
Yolanda Mabry
NPI 1356116149
$761.03
in general payments reported to CMS, 2019-2025
21 companies · $573 in 2025
The $573 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $188 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $761.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $134.10 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $64.46 | 2024-2025 | Calquence, Farxiga, Airsupra |
| Regeneron Healthcare Solutions, INC. | $58.02 | 2025 | Libtayo |
| Glaxosmithkline, LLC. | $57.11 | 2025 | Ojjaara, Jemperli, Zejula |
| Janssen Biotech, INC. | $55.68 | 2025 | Rybrevant |
| Lilly USA, LLC | $51.57 | 2024-2025 | Jaypirca, Zepbound, Mounjaro |
| Deciphera Pharmaceuticals INC. | $31.73 | 2025 | Romvimza, Qinlock |
| Takeda Pharmaceuticals U.S.A., INC. | $31.51 | 2025 | Iclusig |
| Bayer Healthcare Pharmaceuticals INC. | $30.74 | 2024 | |
| Daiichi Sankyo INC. | $26.57 | 2025 | Datroway |
| Spectrum Pharmaceuticals INC. | $25.97 | 2025 | Rolvedon |
| Taiho Oncology, INC. | $24.48 | 2025 | |
| Pharmacosmos Therapeutics INC. | $24.30 | 2025 | Monoferric |
| Merck Sharp & Dohme LLC | $24.13 | 2025 | Keytruda, Lynparza |
| Genentech USA, INC. | $24.01 | 2025 | Venclexta |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.35 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $17.86 | 2025 | Opdivo |
| Genzyme Corporation | $17.43 | 2025 | |
| Novo Nordisk INC | $15.98 | 2025 | Ozempic |
| Idorsia Pharmaceuticals US INC | $15.08 | 2024 | Quviviq |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.95 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yolanda Mabry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.